TARA-002 in Lymphatic Malformations (LMs) - LMs represent a significant pediatric rare disease opportunity with no currently approved therapies[8] - TARA-002 has the potential to treat macrocystic and mixed cystic LMs, which most often are present in the head and neck region[11] - The incidence of LMs is approximately 1,400-1,800 cases per year, with a prevalence of approximately 20,000 patients seeking treatment[14] - Macrocystic LMs account for approximately 47%, microcystic LMs for approximately 21%, and mixed LMs for approximately 32% of cases[14] STARBORN-1 Interim Data - In the STARBORN-1 trial, TARA-002 demonstrated clinical success in 80% of patients that completed treatment[30] - Among evaluable patients in STARBORN-1, TARA-002 showed a 100% clinical success rate at 8-weeks post-treatment[30] - In evaluable patients, 83% with macrocystic LMs, 100% with mixed-cystic LMs and 100% with Ranula achieved complete or substantial response[35] - In the STARBORN-1 trial, 66.7% of patients experienced any grade TEAEs, with 8.3% experiencing Grade 3 TEAEs and no Grade 4/5 TEAEs[39] OK-432 Data Review - OK-432, the predecessor compound to TARA-002, has shown strong safety and efficacy results in over 500 U S pediatric LMs patients in a University of Iowa-led study[18] - OK-432 demonstrated a 69% clinical success rate in the immediate treatment group 6 months after enrollment[46] - OK-432 showed an 84% clinical success rate in patients with macrocystic lesion types[46]

Welcome to Nokia's Capital Markets Day 2025 David Mulholland Head of Investor Relations 1 © 2025 Nokia Public Disclaimer It should be noted that Nokia and its business are exposed to various risks and uncertainties and certain statements herein that are not historical facts are forward-looking statements. These forward-looking statements reflect Nokia's current expectations and views of future developments and include statements preceded by "believe", "expect", "expectations", "ensure", "commit", "anticipat ...

Net sales were 1.5% lower than 2024, and comparable sales declined 2.7%. Bottom line results Home / News & Features COMPANY Q3 2025 Results and Positioning Target for Its Next Chapter of Growth Nov 19, 2025| 5-minute read Copy link to share C- This morning, Target announced our third quarter 2025 earnings. Check out the full results and read on for a snapshot. Q3 2025 results were in line with our expectations Topline sales Adjusted EPS* of $1.78 was about 4% lower than last year, and GAAP EPS was $1.51. Gr ...

RISE UP Phase 3 Trial Results - Mitapivat met the primary endpoint with a 40.6% hemoglobin response rate, defined as ≥1.0 g/dL increase in average Hb from Week 24 through Week 52 compared to baseline, significantly higher than the 2.9% in the placebo arm[38] - There was a trend favoring mitapivat with a 14% reduction in the annualized rate of sickle cell pain crises (SCPCs) compared to placebo, although this did not reach statistical significance[39] - Mitapivat showed a statistically significant improvement in average change from baseline in hemoglobin concentration, with a 7.43 g/L difference compared to placebo[41] - Mitapivat significantly reduced the average change from baseline in indirect bilirubin compared to placebo, with a difference of -16.91 µmol/L[46] - The trial showed a trend in favor of mitapivat with a 14% reduction in the annualized rate of hospitalizations for SCPC compared to placebo[50] - Percent reticulocytes substantially decreased from baseline in the mitapivat arm vs placebo[52] Safety and Discontinuation - The safety profile observed in the RISE UP Phase 3 trial was consistent with previous mitapivat sickle cell disease trials, with no new safety signals identified[57] - The discontinuation rate in the double-blind treatment period was low, with 13% in the mitapivat arm and 18.8% in the placebo arm[34] Next Steps - The company intends to submit a marketing application for mitapivat in the U S for sickle cell disease after a pre-sNDA meeting with the FDA in Q1 2026[61, 68]

Q3 2025 Business Update - Net Yield increased by 7.1% year-over-year[10] - 2025 Advance Bookings reached 96% of Capacity PCD sold[10] - 2026 Advance Bookings reached 70% of Capacity PCD sold[10] Q3 2025 Financial Highlights - Total revenue for the three months ended September 30, 2025, was $2 billion, compared to $1.679 billion in 2024[28] - Adjusted Gross Margin for the three months ended September 30, 2025, was $1.334 billion, compared to $1.099 billion in 2024[28] - Net income for the three months ended September 30, 2025, was $514 million, compared to $380 million in 2024[28] - Adjusted EBITDA for the three months ended September 30, 2025, was $704 million, compared to $554 million in 2024[28] - Adjusted EBITDA Margin was 52.8% for the three months ended September 30, 2025, compared to 50.4% in 2024[28] Viking River and Viking Ocean Key Metrics (Nine Months Ended September 30, 2025) - Consolidated Occupancy was 95.5%[30] - Consolidated Adjusted Gross Margin was $3.184 billion[30] - Consolidated Net Yield was $598[30] Strong Cash Generation and Manageable Bond Maturities - Cash and cash equivalents as of September 30, 2025, were $3 billion[37] - Net Debt as of September 30, 2025, was $2.8 billion[37] - Net Leverage was 1.6x as of September 30, 2025[37] Business Outlook - 2025 Season Advance Bookings reached $5.6 billion, a 21% growth, with 96% Capacity PCD sold[42] - 2026 Season Advance Bookings reached $4.9 billion, a 14% growth, with 70% Capacity PCD sold[44]

3Q25 Earnings Call 19 November 2025 NASDAQ: GDS HKEX: 9698 0 © GDS 2016 DISCLAIMER This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or othe ...

Agenda | Opening Ceremony | Marcel Malczewski - Chairman of the Board of Directors | | --- | --- | | Designing the Future | Daniel Slaviero - President | | Copel Journey 2035: Expansion and Innovation | Diogo Mac Cord - VP of Strategy, New Business and Digital Transformation | | The Compound Factor of Value Creation | Felipe Gutterres - VP of Finance and IR | | Culture as a competitive advantage | Márcia Baena - VP of People and Management | | Legal Intelligence: Lever for Efficiency and Growth | Yuri Ledra ...

VK2735 Development Programs - VANQUISH Phase 3 program is underway for VK2735, a GLP-1/GIP dual agonist for obesity[7, 67] - VENTURE Oral Phase 2 obesity study for VK2735 Oral, a GLP-1/GIP dual agonist, successfully achieved its primary endpoint[7, 10] - An Amylin agonist for obesity has an IND planned for 1Q26[7, 8] - VK2809, a selective thyroid receptor-β agonist for MASH, reported successful Phase 2b data in 2Q24[7, 8] - VK0214, a selective thyroid receptor-β agonist for X-ALD, reported successful Phase 1b data in 4Q24[7, 8] VK2735 Oral Phase 1 Study Results - After 28 days of oral dosing, up to 8.2% reduction in body weight was observed[22] - At 100 mg dose, up to approximately 7% placebo-adjusted weight loss was observed[15] - Weight loss effects were largely maintained through Day 57, four weeks from the last study dose[20] VK2735 VENTURE Oral Phase 2a Study Results - Up to 12.2% reduction from baseline in body weight was observed after 13 weeks[29, 32, 48] - A statistically significant difference vs placebo was observed at all time points for doses >15 mg[34] - In an exploratory maintenance cohort, down-titration from 90mg to 30mg produced continued gradual weight loss through Week 13[42] VK2735 Subcutaneous Formulation VENTURE Phase 2 Study Results - Up to 14.7% mean weight loss was observed after 13 weeks of VK2735 treatment[55, 66] - In the MAD study, a dose-dependent improvement in weight loss of up to 7.8% (6% placebo-adjusted) was reported after 28 days in subjects with BMI ≥30[50] Financial Information - As of September 30, 2025, the company had $714.57 million in cash and short-term investments[74] - Cash burn year-to-date as of September 30, 2025, was $188.042 million[74]

Capital Markets Day Milwaukee, US 19 November 2025 ASSA ABLOY is the global leader in access solutions. Every day we help people feel safe, secure and experience a more open world. Our strategy Build sustainable shareholder value Providing added value to our customers, partners and end-users Being a world leading organization where people can succeed Conducting business in an ethical, compliant and sustainable way Consolidate footprint and focus on value added Optimize logistics Reduce product cost Growth a ...

Company Performance - Qfin Holdings achieved a loan facilitation volume of RMB 833 billion in 3Q25[15] - The company reported a Non-GAAP Net Income of RMB 1508 million in 3Q25[16] - Non-GAAP ROE was 250%[17] User Base and Partnerships - Qfin Holdings has 621 million cumulative users with approved credit lines[15, 24] - The company has established partnerships with 167 financial institutions[15, 24] - The platform services contributed 551% to the loan facilitation volume[60] Shareholder Returns - Over US$1 billion worth of ADSs have been repurchased cumulatively[19] - Share count reduction through share repurchase plans is 228%[19] - The dividend per ADS for 1H25 was US$076[21] Loan Characteristics - The average drawdown is RMB 94k[26] - The weighted average contractual tenor is 106 months[26] - Repeated borrowers' loan volume contribution is 928%[26] AI and Technology - The company processes over 99% of loan applications automatically[43] - The AI-powered credit assessment engine uses over 730k data dimensions and 690 model iterations[43] - 74% of graphics & 27% of videos for marketing are generated by automated AIGC[48]